{
    "clinical_study": {
        "@rank": "131243", 
        "arm_group": [
            {
                "arm_group_label": "Product one", 
                "arm_group_type": "Placebo Comparator", 
                "description": "150 mg (maltodextrin)/day (75 mg maltodextrin included in 280 mg/gelule; 2 times/day: morning and evening) of Placebo plus Dietary Approaches to Stop Hypertension (DASH)"
            }, 
            {
                "arm_group_label": "Product two", 
                "arm_group_type": "Active Comparator", 
                "description": "150 mg Oligopin/day (75mg Oligopin included in 280mg/gelule; 2 times/day: morning and evening) of Oligopin\u00ae plus Dietary Approaches to Stop Hypertension (DASH)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the study is to evaluate the effect of consumption of a food supplement\n      rich in procyanidins extracted from the bark of French pine, Oligopin\u00ae, on blood pressure of\n      people with mild / moderate degree of hypertension. Furthermore, the effect Oligopin\u00ae\n      consumption on markers involved in the development of hypertension, and endothelial function\n      in key enzymes that regulate blood pressure, inflammation and oxidation are considered.\n      Also, try to advance the understanding of the molecular mechanisms that regulate blood\n      pressure."
        }, 
        "brief_title": "Effect of Oligopin\u00ae on Blood Pressure.", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Blood Pressure", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  early stages of hypertension (systolic BP \u2265 140 and \u2264 159 mm Hg) and/or diastolic BP:\n             \u2265 90 and \u2264 99 mm Hg\n\n          -  not receiving BP-lowering medication.\n\n          -  obtained written informed consent before the initial screening visit.\n\n        Exclusion Criteria:\n\n          -  Body Mass Index (BMI) > 30 kg/m2\n\n          -  taking antihypertensive medications\n\n          -  smoking\n\n          -  pregnant or who intends to become pregnant\n\n          -  wife in breastfeeding period\n\n          -  persons with a self-reported history of clinical cardiovascular disease, cancer,\n             chronic kidney disease (or a serum creatinine \u2265 1.7 mg/dL for men and \u2265 1.5 mg/dL for\n             women)  hypercholesterolemia (LDL-c \u2264 189 mg/dL, diabetes mellitus (or serum glucose\n             \u2265126 mg/dL), or consumption of more than 14 drinks of alcoholic beverages per week."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063477", 
            "org_study_id": "Oligo_extract"
        }, 
        "intervention": [
            {
                "arm_group_label": "Product one", 
                "description": "The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Product two", 
                "description": "Oligopin\u00ae PUR' expert (%)  is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:\n- TOTAL POLYPHENOL CONTENT > 96\nMONOMERS + PHENOLIC ACIDS 30\nDIMERS                                        >15\nOTHER OLIGOMERS                          50\nPROCYANIDINS CONTENT (GPC) > 67\nThe Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine  + 30 mg magnesium stearate: total weight: 280 mg/gelule", 
                "intervention_name": "Oligopin\u00ae", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "email": "francesc.puiggros@ctns.cat", 
                "last_name": "Francesc Puiggr\u00f2s, Dr.", 
                "phone": "977751382"
            }, 
            "facility": {
                "address": {
                    "city": "Reus", 
                    "country": "Spain", 
                    "state": "Tarragona", 
                    "zip": "43204"
                }, 
                "name": "Technological Center of Nutrition and Health (CTNS)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of a French Maritim Pine Bark Extract Oligopin\u00ae on Blood Pressure: Double Blind, Crossover, Placebo-controlled Nutrition Intervention Trial", 
        "overall_contact": {
            "email": "rosa.sola@urv.cat", 
            "last_name": "Rosa Sol\u00e0, PhD", 
            "phone": "977759300", 
            "phone_ext": "9369"
        }, 
        "overall_official": [
            {
                "affiliation": "Universitat Rovira i Virgili", 
                "last_name": "Rosa M VALLS, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hospital Universitari Sant Joan, Universitat Rovira i Virgili, CTNS", 
                "last_name": "Rosa SOL\u00c0, MD,PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Differences detected on the time evolution of BP  both in two arms of intervention", 
            "safety_issue": "No", 
            "time_frame": "5 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063477"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Anthropometric data (Weight, BMI, Waist circumference)", 
                "safety_issue": "No", 
                "time_frame": "weeks 2, 5, 6, 9"
            }, 
            {
                "measure": "Endothelial function (Laser-Doppler)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 5, 6, 9"
            }, 
            {
                "measure": "Biochemistry for on-going study control (Glucose, Total cholesterol levels, Creatinine, Albumine, Transaminases (GPT, GOT)", 
                "safety_issue": "No", 
                "time_frame": "Week 1"
            }, 
            {
                "measure": "- Biomarkers related with endothelial function (Endotheline-1, Nitrites (NO3), Nitrates (NO2)) - Biomarker related with blood pressure homeostasis (ACE activity)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 5, 6, 9"
            }, 
            {
                "measure": "- Biomarker related with inflammatory processes (High sensitive C Reactive Protein) - Biomarkers of  antioxidant system (Oxidised- LDL levels, Reduced glutathione, Oxidised glutathione, Ratio Glutathione balance)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 5, 6, 9"
            }
        ], 
        "source": "Technological Centre of Nutrition and Health, Spain", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Technological Centre of Nutrition and Health, Spain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}